Advertisement
Home »

WB: Chemoimmunotherapy Not Linked With Overall Benefit Vs. Immunotherapy Alone

May 24, 2023

REFERENCES & ADDITIONAL READING

Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non–Small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90%

https://www.clinical-lung-cancer.com/article/S1525-7304(23)00038-4/fulltext

ABOUT THE EXPERTS

  • Mohsin Shah, MBBS, MSCE

    Mohsin Shah, MBBS, MSCE
    Center for Real-World Effectiveness and Safety of Therapeutics (CREST)
    Department of Biostatistics, Epidemiology, and Informatics
    Perelman School of Medicine
    The University of Pennsylvania

    Mohsin Shah, MBBS, MSCE, has indicated to Physician’s Weekly that he has no financial interests to disclose.

Advertisement

MEETING BRIEFS

Advertisement